ipriflavone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1477 | 35212-22-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M05BX01 | MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Other drugs affecting bone structure and mineralization |
| CHEBI has role | CHEBI:50646 | antiosteoporotic |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postmenopausal osteoporosis | indication | 102447009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 1 | Enzyme | IC50 | 5.53 | DRUG MATRIX | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.60 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| 4032065 | VUID |
| N0000186568 | NUI |
| D01338 | KEGG_DRUG |
| 4032065 | VANDF |
| C0123903 | UMLSCUI |
| CHEBI:31719 | CHEBI |
| CHEMBL165790 | ChEMBL_ID |
| DB13618 | DRUGBANK_ID |
| C018986 | MESH_SUPPLEMENTAL_RECORD_UI |
| 3747 | PUBCHEM_CID |
| 3521 | INN_ID |
| 80BJ7WN25Z | UNII |
| 51487 | RXNORM |
| 004192 | NDDF |
Pharmaceutical products:
None